Acquired resistance to immune checkpoint inhibitors (ICIs) remains a significant challenge in the treatment of metastatic melanoma. Phenotypic plasticity, such as dedifferentiation and transdifferentiation, is an increasingly recognized mechanism for treatment resistance. We present a case of a man in his 70s with metastatic melanoma who experienced progression through sequential treatments including pembrolizumab in combination with the HDAC inhibitor entinostat,…
Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy
medRxiv Oncology | | Knight, A. D., Robitschek, E. J., Lin, J.-R., Frederick, D. T., Shi, A., Larque, A. B., Miao, B., Raghavan, R. S., Sharova, T., Shin, J. H., Sorger, P., Kellis, M., Flaherty, K. T., Hacohen, N., Boland, G. M., Chebib, I., Liu, D., Sullivan, R. J., Mehta, A.
Topics: skin-cancer, blood-cancer, sarcoma, immunotherapy, research